| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.11 | 0.07 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.07 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.07 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.07 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.07 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.07 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.097 | 0.08 |